10 results
Primary: To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with INC280 in patients with cMET positive NSCLC patientsSecondary: 1: To assess clinical activity of…
With this study we will investigate whether it is possible to dituinguish benign from malignant lesions with Virtual Touch IQ. This will decrease the need for additional biopsy. Furthermore it may decrease the false positive ratio of mammography…
Primary objectivesWhat is the quality of MR images acquired on the MR-HIFU breast system in volunteers and patients with a fibroadenoma relative to the quality of MR images acquired on a conventional diagnostic 3-Tesla MRI scanner? We will assess…
The purpose of this study is to develop and validate methods to fuse the molecular information of DOT-images with anatomical information of MRI-images of the human breast.
Validation of 7T breast MRS for monitoring of neo-adjuvant chemotherapy in patients with breast cancer.
To determine the influence of morning versus evening administration on the pharmacokinetics of tamoxifen and its metabolites. Amendment: To determine the influence of time of administration (morning (8 a.m.), afternoon (1 p.m.) and evening (8 p.m…
Primary Objectives: - To assess whether there is an increase in acute severe toxicity (per TKI cohort) 2 weeks after completion of cranial radiotherapy measured with CTCAE v 4.0. - To assess whether there is an increase in neurotoxicity (measured…
This study has been transitioned to CTIS with ID 2023-506786-63-00 check the CTIS register for the current data. Main objective:•To compare the progression-free survival of imlunestrant (Arm A) to the standard comparator of Investigator's…
We will explore the influence of chemotherapy on hair follicles. Scalp cooling works, but not in every patient. When we understand the working mechanism of chemotherapy induced alopecia, we can possibly explain why scalp cooling works in one patient…
To compare invasive disease-free survival (iDFS) for ribociclib + ET versus placebo + ET in patients with HR-positive, HER2-negative, EBCwith high risk of recurrence.